Congressman John Tierney Visits Implant Sciences

Massachusetts Company Is the Only American-Owned Manufacturer of ETD Equipment Approved by the TSA

Marketwired

WILMINGTON, MA--(Marketwire - Feb 19, 2013) - Implant Sciences Corporation (OTCQB: IMSC), a high technology supplier of systems and sensors for homeland security and defense markets, today announced that Massachusetts Congressman John Tierney visited the Company on Monday, February 11th.

Congressman Tierney toured Implant Sciences' headquarters and manufacturing facility where the Company designs and builds its explosives trace detection systems, which are used in airports and other high threat facilities in 39 countries worldwide. During the tour, he also met with Implant Sciences' management team and employees.

"Massachusetts is the proud home of a growing American manufacturer of trace detection systems, capable of sensing microscopic quantities of explosives and narcotics. These systems are vital in the fight against terrorism. I was impressed by Implant Sciences' facilities, management team, and next generation trace detection technologies," stated Congressman Tierney.

"We need to move away from reactive deployments of technology in response to isolated threat events such as the underwear bomber and the liquids bomber. Rather, we should focus on implementing technologies that balance respect and privacy for the traveling public with high standards of detection to identify evolving threats," Tierney added.

"We were honored to receive Congressman Tierney at our headquarters. With our recent TSA approval, we look forward to continuing to drive high-value job creation in our local economy," stated Implant Sciences' President and CEO, Glenn D. Bolduc. "As a company that has more than quadrupled its workforce over the last four years, we are proud to manufacture American-made products and to be located in the great state of Massachusetts."

About Implant Sciences

Implant Sciences is the leader in next generation Explosives Trace Detection (ETD) technology. In January 2013, the Company became only the third ETD manufacturer, and the sole American-owned company, to receive product approval from the US Transportation Security Administration. Implant Sciences develops, manufactures and sells sophisticated sensors and systems for Security, Safety, and Defense (SS&D) markets. The Company has developed proprietary technologies used in its commercial explosives and narcotics trace detection systems, which ship to a growing number of locations domestically and internationally. Implant Sciences' QS-H150 portable explosives trace detector has received Qualified Anti-Terrorism Technology Designation and, in addition to receiving TSA approval for air cargo screening, the Company's QS-B220 has also received a Developmental Testing & Evaluation (DT&E) Designation by the U.S. Department of Homeland Security under the Support Anti-terrorism by Fostering Effective Technology Act of 2002 (the SAFETY Act). For further details on the Company and its products, please visit the Company's website at www.implantsciences.com.

Safe Harbor Statement

This press release may contain certain "forward-looking statements," as that term is defined in the Private Securities Litigation Reform Act of 1995. Such statements are based on management's current expectations and are subject to risks and uncertainties that could cause the Company's actual results to differ materially from the forward-looking statements. Such risks and uncertainties include, but are not limited to, the risks that our markets are subject to technological change and that our success depends on our ability to develop and introduce new products; the risk that our business is subject to intense competition; the risks that our markets are subject to rapid technology change and that our success depends on our ability to develop and introduce new products; the risks that we may not be able to retain our management and key employees or to identify, hire and retain additional personnel as needed; and other risks and uncertainties described in our filings with the Securities and Exchange Commission, including its most recent Forms 10-K, 10-Q and 8-K. Such statements are based on management's current expectations and assumptions which could differ materially from the forward-looking statements.

Contact:


Implant Sciences Corporation
Company
Glenn Bolduc
CEO
978-752-1700
Email Contact

or

Investor
Laurel Moody
646-810-0608
Email Contact

Rates

View Comments (0)